Squamous Cell Carcinoma of Unknown Primary: Clinical Trials

1 trial for Squamous Cell Carcinoma of Unknown Primary, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 21Completed 1
Phase 31Completed 1

Follow Squamous Cell Carcinoma of Unknown Primary: new trials by email Literature Review of Squamous Cell Carcinoma of Unknown Primary trials Research Report on Squamous Cell Carcinoma of Unknown Primary

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)1962018-04-032026-08-27

Narrower conditions

Carcinoma (1)  ·  Hypopharyngeal Neoplasms (1)  ·  Laryngeal Neoplasms (1)  ·  Mouth Neoplasms (1)  ·  Oropharyngeal Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Broader conditions

Carcinoma, Squamous Cell (1)  ·  Head and Neck Neoplasms (1)  ·  Laryngeal Diseases (1)  ·  Mouth Diseases (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Glandular and Epithelial (1)  ·  Otorhinolaryngologic Diseases (1)  ·  Otorhinolaryngologic Neoplasms (1)  ·  Pharyngeal Diseases (1)  ·  Pharyngeal Neoplasms (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)  ·  Stomatognathic Diseases (1)

Interventions

(225)Ac-DOTA-c(RGDyK) (1)  ·  Cetuximab (1)  ·  Disulfides (1)  ·  Immunoglobulin G (1)  ·  Radiotherapy, Intensity-Modulated (1)  ·  durvalumab (1)

Sponsors

National Cancer Institute (NCI) (1)

Countries

Canada (1)  ·  United States (1)

Top investigators

Loren K Mell (1)

Results publications

PMID 39551064

NIH funding

U10CA180868 (1)